{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:02:27Z","timestamp":1784127747067,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K09746"],"award-info":[{"award-number":["JP21K09746"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00417-021-05517-1","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:03:06Z","timestamp":1642291386000},"page":"1857-1865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study"],"prefix":"10.1007","volume":"260","author":[{"given":"Tamaki","family":"Tamashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Itagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Maruko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorako","family":"Wakugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusaburo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuju","family":"Sekiryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A.","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-4386","authenticated-orcid":false,"given":"Hideki","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Japan AMD Research Consortium (JARC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,16]]},"reference":[{"key":"5517_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I (2008) The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 115:116\u2013126","journal-title":"Ophthalmology"},{"key":"5517_CR2","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/2474126417725946","volume":"1","author":"D Brown","year":"2017","unstructured":"Brown D, Heier JS, Boyer DS, Freund KB, Kaiser P, Kim JE, Sarraf D (2017) Current best clinical practices\u2014management of neovascular AMD. Journal of VitreoRetinal Diseases 1:294\u2013297. https:\/\/doi.org\/10.1177\/2474126417725946","journal-title":"Journal of VitreoRetinal Diseases"},{"key":"5517_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"5517_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"5517_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"5517_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/bjo.2011.203893","volume":"96","author":"MS Eghoj","year":"2012","unstructured":"Eghoj MS, Sorensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21\u201323. https:\/\/doi.org\/10.1136\/bjo.2011.203893","journal-title":"Br J Ophthalmol"},{"key":"5517_CR7","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106-116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"5517_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, Hoerauf H, Lanzetta P, Michels S, Mitchell P, Mones J, Regillo C, Tadayoni R, Talks J, Wolf S (2015) Treat-and-extend regimens with anti-vegf agents in retinal diseases: a literature review and consensus recommendations. Retina 35:1489\u20131506. https:\/\/doi.org\/10.1097\/IAE.0000000000000627","journal-title":"Retina"},{"key":"5517_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG, Hawk IHS (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"5517_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","volume":"146","author":"RF Spaide","year":"2008","unstructured":"Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496\u2013500. https:\/\/doi.org\/10.1016\/j.ajo.2008.05.032","journal-title":"Am J Ophthalmol"},{"key":"5517_CR11","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1167\/iovs.09-4383","volume":"51","author":"Y Ikuno","year":"2010","unstructured":"Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51:2173-2176 iovs.09 4383. https:\/\/doi.org\/10.1167\/iovs.09-4383","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"5517_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00417-011-1620-1","volume":"249","author":"H Koizumi","year":"2011","unstructured":"Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S (2011) Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 249:1123\u20131128. https:\/\/doi.org\/10.1007\/s00417-011-1620-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5517_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.ophtha.2010.09.012","volume":"118","author":"SE Chung","year":"2011","unstructured":"Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118:840-845 S0161-6420(10)00980\u20132. https:\/\/doi.org\/10.1016\/j.ophtha.2010.09.012","journal-title":"Ophthalmology"},{"key":"5517_CR14","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/IAE.0000000000000086","volume":"34","author":"T Yamazaki","year":"2014","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2014) Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 34:1316\u20131322. https:\/\/doi.org\/10.1097\/IAE.0000000000000086","journal-title":"Retina"},{"key":"5517_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00417-015-3260-3","volume":"254","author":"C Yun","year":"2016","unstructured":"Yun C, Oh J, Ahn J, Hwang SY, Lee B, Kim SW, Huh K (2016) Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 254:1693\u20131702. https:\/\/doi.org\/10.1007\/s00417-015-3260-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5517_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","volume":"119","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S (2012) Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 119:1621\u20131627. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.022","journal-title":"Ophthalmology"},{"key":"5517_CR17","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1136\/bjophthalmol-2014-306432","volume":"99","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2015) Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol 99:1284\u20131288. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306432","journal-title":"Br J Ophthalmol"},{"issue":"627\u2013633","key":"5517_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.12.025","volume":"159","author":"H Koizumi","year":"2015","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Kawasaki R, Sekiryu T, Okada AA, Iida T (2015) Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 159(627\u2013633):e621. https:\/\/doi.org\/10.1016\/j.ajo.2014.12.025","journal-title":"Am J Ophthalmol"},{"key":"5517_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","volume":"123","author":"H Koizumi","year":"2016","unstructured":"Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T (2016) Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results. Ophthalmology 123:617\u2013624. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.039","journal-title":"Ophthalmology"},{"key":"5517_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","volume":"15","author":"RF Spaide","year":"1995","unstructured":"Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA (1995) Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 15:100\u2013110","journal-title":"Retina"},{"key":"5517_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","volume":"21","author":"LA Yannuzzi","year":"2001","unstructured":"Yannuzzi LA, Negrao S, Iida T, Carvalho C, Rodriguez-Coleman H, Slakter J, Freund KB, Sorenson J, Orlock D, Borodoker N (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416\u2013434","journal-title":"Retina"},{"key":"5517_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Mones JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636. https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.004","journal-title":"Ophthalmology"},{"key":"5517_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15\u201322","journal-title":"Am J Ophthalmol"},{"key":"5517_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G, (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509\u2013516. https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","journal-title":"Am J Ophthalmol"},{"key":"5517_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/OPTH.S30907","volume":"6","author":"AA Ellabban","year":"2012","unstructured":"Ellabban AA, Tsujikawa A, Ogino K, Ooto S, Yamashiro K, Oishi A, Yoshimura N (2012) Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Clin Ophthalmol 6:837\u2013844. https:\/\/doi.org\/10.2147\/OPTH.S30907","journal-title":"Clin Ophthalmol"},{"key":"5517_CR26","doi-asserted-by":"publisher","first-page":"44020","DOI":"10.1038\/srep44020","volume":"7","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A, Mabuchi F, Iijima H (2017) Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. Sci Rep 7:44020. https:\/\/doi.org\/10.1038\/srep44020","journal-title":"Sci Rep"},{"key":"5517_CR27","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00417-017-3718-6","volume":"255","author":"M Morimoto","year":"2017","unstructured":"Morimoto M, Matsumoto H, Mimura K, Akiyama H (2017) Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 255:1891\u20131897. https:\/\/doi.org\/10.1007\/s00417-017-3718-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5517_CR28","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1097\/IAE.0000000000001104","volume":"36","author":"H Matsumoto","year":"2016","unstructured":"Matsumoto H, Sato T, Morimoto M, Mukai R, Takahashi M, Hiroe T, Ehara K, Takayama M, Mimura K, Kishi S (2016) Treat-and-extend regimen with aflibercept for retinal angiomatous proliferation. Retina 36:2282\u20132289. https:\/\/doi.org\/10.1097\/IAE.0000000000001104","journal-title":"Retina"},{"key":"5517_CR29","doi-asserted-by":"publisher","first-page":"6759","DOI":"10.1038\/s41598-021-86014-7","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto H, Hoshino J, Mukai R, Nakamura K, Akiyama H (2021) Short-term outcomes of intravitreal brolucizumab for treatment-naive neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy. Sci Rep 11:6759. https:\/\/doi.org\/10.1038\/s41598-021-86014-7","journal-title":"Sci Rep"},{"key":"5517_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10384-015-0411-3","volume":"60","author":"M Saito","year":"2016","unstructured":"Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T (2016) Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Jpn J Ophthalmol 60:35\u201341. https:\/\/doi.org\/10.1007\/s10384-015-0411-3","journal-title":"Jpn J Ophthalmol"},{"key":"5517_CR31","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ajo.2010.10.030","volume":"151","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T (2011) Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 151:594-603 e591 S0002-9394(10)00839\u20131. https:\/\/doi.org\/10.1016\/j.ajo.2010.10.030","journal-title":"Am J Ophthalmol"},{"key":"5517_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.exer.2007.05.008","volume":"85","author":"J Lowe","year":"2007","unstructured":"Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Experimental eye Res 85:425-430 S0014-4835(07)00153\u20134. https:\/\/doi.org\/10.1016\/j.exer.2007.05.008","journal-title":"Experimental eye Res"},{"key":"5517_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171\u2013185. https:\/\/doi.org\/10.1007\/s10456-011-9249-6","journal-title":"Angiogenesis"},{"key":"5517_CR34","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ophtha.2020.03.031","volume":"127","author":"SR Sadda","year":"2020","unstructured":"Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S (2020) Spectral-domain OCT analysis of risk factors for macular atrophy development in the HARBOR study for neovascular age-related macular degeneration. Ophthalmology 127:1360\u20131370. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.031","journal-title":"Ophthalmology"},{"key":"5517_CR35","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/IAE.0000000000001765","volume":"38","author":"Y Kuroda","year":"2018","unstructured":"Kuroda Y, Yamashiro K, Ooto S, Tamura H, Oishi A, Nakanishi H, Miyata M, Hata M, Takahashi A, Wakazono T, Yoshimura N, Tsujikawa A (2018) Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration. Retina 38:1743\u20131750. https:\/\/doi.org\/10.1097\/IAE.0000000000001765","journal-title":"Retina"},{"key":"5517_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10384-020-00745-0","volume":"64","author":"H Koizumi","year":"2020","unstructured":"Koizumi H, Yamamoto A, Ogasawara M, Maruko I, Hasegawa T, Itagaki K, Sekiryu T, Okada AA, Iida T (2020) Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Jpn J Ophthalmol 64:338\u2013345. https:\/\/doi.org\/10.1007\/s10384-020-00745-0","journal-title":"Jpn J Ophthalmol"},{"key":"5517_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011","author":"J Mones","year":"2020","unstructured":"Mones J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS (2020) Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2020.11.011","journal-title":"Ophthalmology"},{"key":"5517_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.09.020","author":"CR Baumal","year":"2020","unstructured":"Baumal CR, Bodaghi B, Singer M, Tanzer DJ, Seres A, Joshi MR, Feltgen N, Gale R (2020) Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2020.09.020","journal-title":"Ophthalmol Retina"},{"key":"5517_CR39","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1007\/s00417-021-05136-w","volume":"259","author":"I Maruko","year":"2021","unstructured":"Maruko I, Okada AA, Iida T, Hasegawa T, Izumi T, Kawai M, Maruko R, Nakayama M, Yamamoto A, Koizumi H, Tamashiro T, Terao N, Wakugawa S, Mori R, Onoe H, Tanaka K, Wakatsuki Y, Itagaki K, Kasai A, Ogasawara M, Sekiryu T, Shintake H, Sugano Y, Japan AMDRC (2021) Brolucizumab-related intraocular inflammation in Japanese patients with age-related macular degeneration: a short-term multicenter study. Graefes Arch Clin Exp Ophthalmol 259:2857\u20132859. https:\/\/doi.org\/10.1007\/s00417-021-05136-w","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"5517_CR40","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1167\/iovs.10-6811","volume":"52","author":"Y Ikuno","year":"2011","unstructured":"Ikuno Y, Maruko I, Yasuno Y, Miura M, Sekiryu T, Nishida K, Iida T (2011) Reproducibility of retinal and choroidal thickness measurements in enhanced depth imaging and high-penetration optical coherence tomography. Invest Ophthalmol Vis Sci 52:5536\u20135540. https:\/\/doi.org\/10.1167\/iovs.10-6811","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05517-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T10:05:15Z","timestamp":1651485915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05517-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5517"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05517-1","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board of each university and was conducted in accordance with the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all the patients included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Dr. Tamashiro reported personal fees from Alcon, Novartis, and Senju outside the submitted work. Dr. Tanaka reported personal fees from Alcon, Bayer, Novartis, Santen, and Senju outside the submitted work. Dr. Itagaki reported personal fees from Bayer and Novartis outside the submitted work. Dr. Nakayama has nothing to disclose. Dr. Maruko reported grants from JSPS KAKENHI (Grant Number JP20K09781); personal fees from Alcon, Bayer, Canon, Nidek, Novartis, Santen, Senju, and Topcon outside the submitted work. Dr. Wakugawa reported personal fees from Senju and Novartis outside the submitted work. Dr. Terao reported personal fees from Bayer, Nidek, Novartis, Senju, Santen, and Topcon outside the submitted work. Dr. Onoe reported personal fees from AMO and Novartis outside the submitted work. Dr. Wakatsuiki reported personal fees from Bayer outside the submitted work. Dr. Ogasawara has nothing to disclose. Dr. Sugano has nothing to disclose. Dr. Yamamoto reported personal fees from Alcon, Bayer, Novartis, Otsuka, and Santen outside the submitted work. Dr. Kataoka reported personal fees from Bayer, Novartis, Santen, and Senju outside the submitted work. Dr. Izumi reported personal fees from Senju and Topcon outside the submitted work. Dr. Kawai has nothing to disclose. Dr. Mori reported personal fees from Novartis, Bayer, Senju, Santen, Bausch & Lomb, JFC, Nikon, and Acula outside the submitted work. Dr. Sekiryu reported personal fees from Novartis, Bayer, Senju, Santen, Kowa, Allergan, and Chugai outside the submitted work. Dr. Okada reported consulting fees from Astellas, Bayer, Biocon Biologics, Daiichi Sankyo, HOYA, Kowa, and Novartis; personal support from Abbvie, Alcon, Bayer, Mitsubishi Tanabe, Novartis, Pfizer, Santen, and Senju outside the submitted work. Dr. Iida reported consulting fees from Bayer and Chugai; personal fees from AMO, Alcon, Bayer, Canon, HOYA, JFC, Kowa, Nikon, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju, and Topcon outside the submitted work. Dr. Koizumi reported grants from JSPS KAKENHI (Grant Number JP21K09746); personal fees from Novartis, Alcon, Bayer, Canon, Senju, Santen, Kowa, HOYA, AMO, Otsuka, Pfizer, Allergan, Bausch & Lomb, JFC, Nidek, Topcon, Abbvie, TOMEY, Sumitomo Dainippon Pharma, Chugai, and SANOFI outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}